{"id":13382,"date":"2022-05-02T12:46:08","date_gmt":"2022-05-02T12:46:08","guid":{"rendered":"https:\/\/laforcedmd.com\/go-further-who-decides-to-reimburse-drug-costs\/"},"modified":"2022-10-27T19:29:03","modified_gmt":"2022-10-27T19:29:03","slug":"go-further-who-decides-to-reimburse-drug-costs","status":"publish","type":"page","link":"https:\/\/laforcedmd.com\/en\/go-further-who-decides-to-reimburse-drug-costs\/","title":{"rendered":"Go further – Who decides to reimburse drug costs?"},"content":{"rendered":"
[mk_page_section vertical_align=”center” bg_image=”https:\/\/laforcedmd.com\/wp-content\/uploads\/2022\/06\/img-la-force-dmd-19.jpg” bg_position=”center center” bg_repeat=”no-repeat” bg_stretch=”true” enable_3d=”true” min_height=”250″ full_height=”true” el_class=”section-header header-02″ sidebar=”sidebar-1″][vc_column][vc_column_text disable_pattern=”false” align=”center” css=”.vc_custom_1653673400308{margin-bottom: 0px !important;}”]\n

Who decides to reimburse<\/span>
\nWho decides whether or not to<\/span><\/h1>\n[\/vc_column_text][\/vc_column][\/mk_page_section][vc_row][vc_column][mk_padding_divider size=”75″][vc_column_text disable_pattern=”false” align=”center” el_class=”contenu-inner-padding” css=”.vc_custom_1654196825443{margin-bottom: 0px !important;}”]\n

Here\u2019s a look at how things work.<\/span><\/h2>\n[\/vc_column_text][mk_padding_divider size=”75″][\/vc_column][\/vc_row][vc_row fullwidth=”true” css=”.vc_custom_1650899369675{padding-right: 0px !important;padding-left: 0px !important;}”][vc_column css=”.vc_custom_1650899375035{padding-right: 0px !important;padding-left: 0px !important;}”][vc_accordions style=”simple-style” container_bg_color=”” responsive=”false” scroll_click=”true” el_class=”liste-accordion liste-remboursement accordion-hide-title”][vc_accordion_tab title=”<\/p>
\n<h2>Who decides to reimburse drug costs?<\/h2>
\n<p>”][vc_row_inner el_class=”border-section” css=”.vc_custom_1651495804444{padding-right: 0px !important;padding-left: 0px !important;}”][vc_column_inner el_class=”bg-height-02″ width=”1\/2″ css=”.vc_custom_1654197319081{padding-right: 0px !important;padding-left: 0px !important;background-image: url(https:\/\/laforcedmd.com\/wp-content\/uploads\/2022\/05\/img-la-force-dmd-20.jpg?id=11349) !important;background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}”][\/vc_column_inner][vc_column_inner width=”1\/2″][vc_column_text disable_pattern=”false” el_class=”contenu-inner-padding” css=”.vc_custom_1654196849359{margin-bottom: 0px !important;}”]\n

Who decides to reimburse drug costs?<\/span><\/h2>\n

After a new drug receives a Notice of Compliance (NOC) and Drug Identification Number (DIN) from Health Canada, a pharmaceutical company can ask provincial or territorial drug insurance plans to reimburse the cost of a new drug. Participating drug plans may also submit requests.<\/p>\n

Here\u2019s a look at how things work. First, it\u2019s worth mentioning that each province and territory in Canada has its own drug reimbursement plan.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_accordion_tab][vc_accordion_tab title=”<\/p>
\n<h3>Across Canada<\/h3>
\n<p>”][vc_row_inner is_fullwidth_content=”false”][vc_column_inner][mk_padding_divider size=”75″][vc_column_text disable_pattern=”false” el_class=”contenu-inner-padding” css=”.vc_custom_1654805335477{margin-bottom: 0px !important;}”]\n

Across Canada<\/span><\/h3>\n

In all Canadian provinces and territories, except Quebec (see below), the Canadian Agency for Drugs and Technologies in Health (CADTH), through the Common Drug Review (CDR) process, decides whether or not to recommend the public reimbursement of new drug costs. (A different process is used for new cancer drugs.) This review process takes 180 days or longer.<\/p>\n

Step 1<\/p>\n

A pharmaceutical company or provincial or territorial drug plan submits its request for a Common Drug Review to CADTH.<\/p>\n

Step 2<\/p>\n

During the CDR process, the Canadian Drug Expert Committee (CDEC) conducts a rigorous, objective evaluation of the drug\u2019s clinical and economic benefits and drawbacks. It then makes a recommendation to federal, provincial and territorial drug insurance plans (except Quebec) to:<\/p>\n